Effects of infused CD34+ cell count on hematopoietic recovery and prognosis of non-Hodgkin lymphoma patients after autologous peripheral blood hematopoietic stem cell transplantation

Abstract

Objective To investigate the effect of infused CD34+ cell count on hematopoietic recovery and prognosis of non-Hodgkin lymphoma (NHL) patients after autologous peripheral blood hematopoietic stem cell transplantation (APBSCT). Methods The data of 60 NHL patients who underwent APBSCT from May 2010 to May 2016 in the Affiliated Cancer Hospital of Shanxi Medical University was retrospectively analyzed, including 32 B-NHL patients and 28 T-NHL patients. The patients were grouped according to the receiver operating characteristic curve (ROC) threshold, and the hematopoietic reconstruction after transplantation was analyzed. The relationship between the infused CD34+ cell count and prognosis was analyzed. The prognostic factors were analyzed using univariate and multivariate analyses. Results The CD34+ cell count threshold was determined to be 4.35×106/kg based on ROC. In CD34+ cell count≥ 4.35×106/kg group (20 cases) and CD34+ cell count 60 years old, Ann Arbor stage Ⅲ-Ⅳ, international prognostic index (IPI) score > 2 and infused CD34+ cell count < 4.35×106/kg (all P < 0.05). Multivariate analysis showed that IPI score and infused CD34+ cell count were both independent predictive factors of PFS (RR = 0.333, 95% CI 0.112-0.994, P = 0.049; RR = 0.190, 95% CI 0.047-0.773, P = 0.020), and IPI score was an independent predictive factor of OS (RR = 0.095, 95% CI 0.011-0.837, P = 0.034). Conclusion The infused CD34+ cell count affects the hematopoietic reconstruction time and component blood transfusion after APBSCT, and has certain predictive value for the prognosis of NHL patients. Key words: Lymphoma, non-Hodgkin; Autologous hematopoietic stem cell transplantation; CD34+ cell count